Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Kite, a Gilead Company (NASDAQ: GILD), has filed a supplemental Biologics License Application (sBLA) with the FDA for Yescarta (axicabtagene ciloleucel) to treat adults with relapsed or refractory large B-cell lymphoma in the second-line setting. The filing is based on the ZUMA-7 study, which showed a significant 60% reduction in the risk of event-free survival compared to standard care over a median follow-up of two years. This would make Yescarta the first CAR T-cell therapy for adults in this group if approved.
Gilead Sciences (GILD) announced that Health Canada has approved Trodelvy (sacituzumab govitecan-hziy) as a second-line treatment for adults with metastatic triple-negative breast cancer (TNBC) who have undergone two or more prior therapies. This approval follows Trodelvy's demonstrated survival benefits in the Phase 3 ASCENT study, showing a 49% reduction in the risk of death. Trodelvy is now authorized in multiple countries, including the U.S., Australia, Great Britain, and Switzerland, under the Project Orbis initiative. Concerns include severe adverse reactions, such as neutropenia and diarrhea.
Gilead Sciences announced positive results from a Phase 3 trial of Veklury (remdesivir) for treating COVID-19 in non-hospitalized patients at high risk of disease progression. The study, involving 562 participants, showed 87% reduction in hospitalization or all-cause death by Day 28 compared to placebo. Additionally, there was an 81% reduction in medical visits due to COVID-19. No deaths were recorded by Day 28. The findings will be presented at IDWeek 2021. Veklury remains investigational for this use, and safety and efficacy for this dosing duration are pending regulatory approval.
Gilead Sciences (Nasdaq: GILD) will present new data at the IDWeek 2021 conference from September 29 to October 3, focusing on COVID-19 and HIV research. Key presentations include real-world analyses of Veklury (remdesivir), highlighting its effectiveness in hospitalized COVID-19 patients regarding mortality and readmission rates. Additionally, findings on the HIV treatment Biktarvy and prevention strategies to enhance diversity in clinical trials will be shared. Gilead remains committed to advancing treatment options and addressing health disparities in affected communities.
Gilead Sciences (Nasdaq: GILD) announced promising new data from the Phase 3 ASCENT study of Trodelvy in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC). A subgroup analysis revealed that Trodelvy significantly improved progression-free survival (PFS) to 4.6 months vs. 2.3 months with chemotherapy. Overall survival (OS) was also enhanced, with Trodelvy patients living 12.4 months compared to 6.7 months with chemotherapy. The study enrolled over 500 patients and highlighted Trodelvy's efficacy even in non-TNBC patients, reinforcing its role in cancer treatment.
Gilead Sciences announced results from the Phase 3 ASCENT study for Trodelvy (sacituzumab govitecan-hziy) in patients with relapsed or refractory triple-negative breast cancer (TNBC). The study showed Trodelvy improved overall survival (11.8 months vs. 6.9 months, p<0.0001) and significantly enhanced health-related quality of life (HRQoL) compared to physician's choice chemotherapy. Patients reported better global health status and lower symptomatic impacts of fatigue, pain, and insomnia. Trodelvy offers a vital treatment option for this aggressive cancer type.
Gilead Sciences (Nasdaq: GILD) presented new research on Trodelvy (sacituzumab govitecan-hziy) at the ESMO Congress 2021, highlighting its efficacy in treating metastatic triple-negative breast cancer (TNBC). The data from the Phase 3 ASCENT study suggests Trodelvy improves health-related quality of life (HRQoL) compared to single-agent chemotherapy. Gilead aims to expand Trodelvy's potential across various advanced solid tumors. The press release underscores Gilead's commitment to addressing high unmet medical needs in oncology.
Gilead Sciences (Nasdaq: GILD) announced its participation in the Morgan Stanley Annual Global Healthcare Conference on
Gilead Sciences (Nasdaq: GILD) announced the full validation of its Marketing Authorization Application (MAA) for lenacapavir, an investigational HIV-1 capsid inhibitor, by the European Medicines Agency (EMA). This application targets treatment for adults with multidrug resistant HIV-1 infection who are on a failing regimen. The EMA’s Committee for Medicinal Products for Human Use will assess the application. Lenacapavir showed promising results in the CAPELLA study, with 88% of participants achieving significant viral load reduction. It remains investigational and is not yet approved.
Kite, a Gilead Company (Nasdaq: GILD), has partnered with Appia Bio to develop engineered allogeneic cell therapies for hematological malignancies. The collaboration focuses on creating chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s ACUA technology. Appia Bio will lead preclinical and early clinical research, while Kite will oversee development and commercialization. The agreement includes an upfront payment, equity investment, and up to $875 million in milestone payments, signaling a strong commitment to advancing innovative cancer therapies.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
